Welcome to our dedicated page for Liveworld news (Ticker: LVWD), a resource for investors and traders seeking the latest updates and insights on Liveworld stock.
Liveworld, Inc. (LVWD) delivers essential social content management solutions for global brands through its unique blend of proprietary technology and human expertise. This news hub provides investors and industry professionals with timely updates on corporate developments, financial performance, and strategic initiatives shaping the content moderation landscape.
Access official press releases covering earnings announcements, partnership agreements, technology innovations, and leadership updates. Our curated selection enables stakeholders to track LVWD's progress in maintaining brand safety across social platforms while driving meaningful customer engagement.
Key updates include regulatory compliance developments, platform enhancements for real-time content analysis, and expansion into new verticals. Bookmark this page for direct access to verified information about LVWD's operational milestones and market positioning within the digital content management sector.
LiveWorld (OTC: LVWD) has unveiled its first AI Brand Reputation Index, analyzing how artificial intelligence influences perceptions of 50 leading pharmaceutical brands. The study, released on April 15, 2025, employs LiveWorld's proprietary AI framework to evaluate seven weighted reputation factors across major language models including ChatGPT, Perplexity, and Grok.
The index revealed that established brands like Dupixent and Keytruda maintain strong AI reputations due to clinical effectiveness and healthcare professional trust. Notably, Vertex Pharmaceuticals' Trikafta topped the rankings despite advertising, while newer therapies like Leqvio and Rybrevant struggle with AI visibility. The study also highlighted how safety concerns impact AI-driven reputation for products like Remicade and Xeljanz.
The assessment factors included:
- Efficacy
- Safety
- Healthcare professional trust
- Consumer sentiment
- Digital visibility
- Affordability
- Patient loyalty
LiveWorld (LVWD) has reported its financial results for 2024, showing total revenues of $11.3 million, a 1% decrease from 2023. The company's healthcare segment generated $10.2 million in revenue. Despite market challenges, LiveWorld achieved a net income of $69,000, down from $214,000 in 2023.
The company's cash position strengthened significantly, with net cash increasing by $1.6 million to $6.2 million at year-end. LiveWorld has developed an AI strategic roadmap and is increasing investments in AI solutions, integrating human expertise with machine learning and analytics.
Management anticipates continued market uncertainty in 2025 and warns that ongoing investments may result in losses. However, they expect their AI-human intelligence blend to drive medium and long-term revenue growth.
LiveWorld (OTC: LVWD), a social-first digital agency focusing on healthcare and pharma brands, has appointed Carl Gustin to its Board of Directors. Gustin, currently Chief Strategy & Marketing Officer at SpeciCare, brings extensive experience in healthcare, technology, and AI-driven business transformation.
Gustin's background includes notable positions as Chief Marketing Officer at Kodak, where he led digital transformation efforts, and involvement in launching Apple's first PowerBook. He has been recognized as an Ad Age Top 50 Marketer.
The appointment aligns with LiveWorld's strategy to enhance its AI-driven solutions and expand its presence in the healthcare sector. The company, with 28 years of experience in digital engagement, aims to strengthen its position in pharmaceutical and healthcare marketing through innovative and compliant social media strategies.
LiveWorld (LVWD) reported Q3 2024 financial results showing significant growth. Total revenues reached $3.1 million, up 13% year-over-year, with healthcare revenues growing 17% to $2.6 million. Net income from operations improved to $291,000, a substantial increase from $46,000 in Q3 2023. Cash position strengthened to $6.2 million, up $1.5 million from December 2023. The company expects 15-20% revenue growth in H2 2024 compared to H1. Despite facing corporate marketing budget constraints and client attrition, LiveWorld has offset these challenges with new client acquisitions and existing client growth.
LiveWorld, Inc. (OTC Markets: LVWD) and Sermo have released findings from a survey of 317 US physicians across ten therapeutic categories, confirming the significant influence of Key Opinion Leaders (KOLs) and Digital Opinion Leaders (DOLs) on Healthcare Providers' (HCPs) prescribing behavior. Key findings include:
- 60% of HCPs changed perceptions of medications based on influencer social media content
- 50% changed prescriptions due to influencer content
- 69% engage with influencer content daily
The survey highlights preferences for platforms like Sermo, Instagram, and LinkedIn, with content types such as Q&A sessions and case studies being most engaging. Credibility factors for influencers include credentials, peer endorsements, and evidence-based content. The study also provides insights into generational and specialty-specific preferences, emphasizing the shift in medical information dissemination in the digital age.
LiveWorld, Inc. (OTC: LVWD) reported its Q2 2024 financial results, showing a decrease in revenues and a net loss from operations. Key highlights include:
- Total revenues of $2.8 million, down 9% year-over-year
- Healthcare revenues of $2.4 million
- Net loss from operations of ($134,000)
- Cash increased by $136,000 to $4.8 million
The company expects flat revenues for 2024 compared to 2023 due to tightened corporate budgets and client program attrition. LiveWorld is investing in new solutions and market segments, aiming for future growth in 2025 and beyond.
LiveWorld (OTC Markets: LVWD) announced its financial results for Q1 2024, reporting total revenues of $2.6 million, a 6% decrease from the same period in 2023. Healthcare revenues accounted for $2.3 million. The company recorded a net loss of $498,000, compared to a net income of $134,000 in Q1 2023. Cash reserves decreased by $320,000 to $4.3 million. The company added pharma executives Helen Chang and Jennifer Sherak to its board and published a business report detailing its growth strategy. Management expects reduced losses and increased revenue in the upcoming quarters.
FAQ
What is the current stock price of Liveworld (LVWD)?
What is the market cap of Liveworld (LVWD)?
